1+ hour, 45+ min ago   (717+ words) During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal cell carcinoma, highlighting management of anemia and hypoxia. This article is part 2 of a 2-part series from a Case-Based Roundtable event....

3+ hour, 52+ min ago   (420+ words) During his presentation at the 4th Annual Miami Cancer Institute Precision Oncology Symposium, Petros Grivas, MD, PhD, FASCO, provided a detailed roadmap for community oncologists with an emphasis on precision medicine. The frontline paradigm for metastatic UC is now clearly defined,…...

4+ hour, 56+ min ago   (587+ words) Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies. The FDA has accepted for review a new drug application (NDA) for zanzalintinib (formerly XL092) combined with atezolizumab (Tecentriq) for treatment of adult patients…...

4+ hour, 56+ min ago   (234+ words) The FDA granted orphan drug designation to IFx-2.0, an injection designed to enhance immune response, in cutaneous melanoma. The FDA has granted orphan drug designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma based…...

4+ hour, 58+ min ago   (457+ words) Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment'Targeted Oncology Pancreatic cancer remains one of the most aggressive and challenging malignancies to treat, with limited effective options and historically poor outcomes. While chemotherapy is the predominant approach by…...

8+ hour, 44+ min ago   (340+ words) FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC'Targeted Oncology The FDA has accepted and granted priority review to the supplemental biologics license application (sBLA) for datopotamab deruxtecan (Dato-DXd; Datroway) for the treatment of adult patients with unresectable or metastatic…...

14+ hour, 30+ min ago   (138+ words) Targeted Oncology: Could you provide a high-level overview of your talk at the symposium? How should clinicians think about sequencing if a patient is eligible for both an ADC and standard chemotherapy or chemoimmunotherapy? Based on your experience, what are…...

14+ hour, 30+ min ago   (286+ words) New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer. The exploratory analysis followed primary results previously reported at the 2024 San Antonio Breast Cancer Symposium. While the initial data demonstrated promising antitumor…...

14+ hour, 31+ min ago   (381+ words) Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care. Due to the prespecified hierarchical testing method, relapse-free survival (RFS) results were not considered statistically significant after the second end point…...

1+ day, 5+ hour ago   (252+ words) The FDA has granted approval to Guardant360 CDx, a companion diagnostic to help identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with encorafenib (Braftovi) plus cetuximab (Erbitux) and chemotherapy.1 This approval adds to its expanding portfolio…...